Morgan Stanley
MRVI icon

Morgan Stanley’s Maravai LifeSciences MRVI Stock Holding History

Morgan Stanley’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.9M Sell
1,908,276
-1,411,049
-43% -$6.09M ﹤0.01% 3555
2026
Q1 		$9.39M Sell
3,319,325
-127,477
-4% -$432K ﹤0.01% 3614
2025
Q4 		$11.2M Buy
3,446,802
+563,035
+20% +$1.9M ﹤0.01% 3513
2025
Q3 		$8.28M Buy
2,883,767
+6,727
+0.2% +$17.2K ﹤0.01% 3705
2025
Q2 		$6.93M Buy
2,877,040
+342,069
+13% +$719K ﹤0.01% 3787
2025
Q1 		$5.6M Buy
2,534,971
+301,902
+14% +$1.19M ﹤0.01% 3838
2024
Q4 		$12.2M Sell
2,233,069
-466,670
-17% -$3M ﹤0.01% 3244
2024
Q3 		$22.4M Buy
2,699,739
+979,391
+57% +$8.47M ﹤0.01% 2687
2024
Q2 		$12.3M Sell
1,720,348
-884,418
-34% -$7.64M ﹤0.01% 3150
2024
Q1 		$22.6M Sell
2,604,766
-264,382
-9% -$1.79M ﹤0.01% 2559
2023
Q4 		$18.8M Buy
2,869,148
+1,442,909
+101% +$9.32M ﹤0.01% 2748
2023
Q3 		$14.3M Sell
1,426,239
-404,475
-22% -$4.44M ﹤0.01% 2793
2023
Q2 		$22.8M Sell
1,830,714
-702,218
-28% -$9.48M ﹤0.01% 2350
2023
Q1 		$35.5M Buy
2,532,932
+706,814
+39% +$10.2M ﹤0.01% 1863
2022
Q4 		$26.1M Buy
1,826,118
+522,612
+40% +$8.23M ﹤0.01% 2068
2022
Q3 		$33.3M Sell
1,303,506
-1,531,611
-54% -$38.4M ﹤0.01% 1670
2022
Q2 		$80.5M Sell
2,835,117
-7,904
-0.3% -$250K 0.01% 1058
2022
Q1 		$100M Buy
2,843,021
+322,568
+13% +$10.8M 0.01% 865
2021
Q4 		$106M Sell
2,520,453
-27,598
-1% -$1.12M 0.01% 859
2021
Q3 		$125M Buy
2,548,051
+636,173
+33% +$31M 0.02% 714
2021
Q2 		$79.8M Buy
1,911,878
+504,083
+36% +$19.5M 0.01% 991
2021
Q1 		$50.2M Buy
1,407,795
+1,381,269
+5,207% +$45.8M 0.01% 1171
2020
Q4 		$744K Buy
+26,526
New +$739K ﹤0.01% 4833

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Morgan Stanley's MRVI Position: Q2 2026 in Review

Morgan Stanley reduced its Maravai LifeSciences (MRVI) stake by 43% in Q2 2026, selling an estimated $6.09M and leaving 1,908,276 shares worth $11.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3555.

Morgan Stanley first reported a position in MRVI in Q4 2020 and has held it in 23 quarters since. The position peaked at $125M in Q3 2021. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Morgan Stanley held 1,908,276 shares of Maravai LifeSciences worth $11.9M as of Q2 2026.
  • Morgan Stanley sold 1,411,049 Maravai LifeSciences shares in Q2 2026, an estimated $6.09M.
  • Maravai LifeSciences made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3555 holding.
  • Morgan Stanley first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 23 quarters since.
  • Morgan Stanley's Maravai LifeSciences position peaked at $125M in Q3 2021.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.